Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Pemetrexed 6Cisplatin 6Nivolumab 5Gemcitabine 5Drug Therapy 5Radiotherapy 4Docetaxel 4pembrolizumab 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Endostatins 3Carboplatin 3tislelizumab 2endostar protein 2durvalumab 2camrelizumab 2Thalidomide 2Paclitaxel 2Oxaliplatin 2Irinotecan 2Gefitinib 2Erlotinib Hydrochloride 2Bevacizumab 2Afatinib 2trilaciclib 1toripalimab 1titanium silicide 1osimertinib 1olaparib 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Carcinoma, Non-Small-Cell Lung × Blood Cell Count × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡